Summary: S.2476 — 115th Congress (2017-2018)All Information (Except Text)

There is one summary for S.2476. Bill summaries are authored by CRS.

Shown Here:
Introduced in Senate (02/28/2018)

Expanding Access to Low Cost Generic Drugs Act

This bill amends the Federal Food, Drug, and Cosmetic Act to disqualify from receiving market exclusivity a generic drug manufacturer who enters into an agreement with the patent holder for a brand name drug to delay getting the generic drug approved or to delay marketing it.